Take­da CEO Christophe We­ber will step down next June af­ter more than 10 years lead­ing the Japan­ese drug­mak­er. Julie ...

Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...

Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...

Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...

Fertility startup Gameto has received permission from the FDA to see if its ovary-in-a-dish technology can make in vitro ...

The Trump ad­min­is­tra­tion said on Wednes­day it will con­sid­er “op­por­tu­ni­ties to bring greater trans­paren­cy” to the ...

Teva CEO Richard Francis expects continued growth for Austedo despite future Medicare price negotiations, maintaining $2.5B ...

VC, a venture capital firm that has spread its bets across multiple industries, including biotech and digital health, is ...

Em­bat­tled ge­net­ics test­ing gi­ant 23andMe is think­ing of sell­ing it­self as it runs out of cash. The com­pa­ny needs ...

The first of two confirmation hearings is now underway for Robert F. Kennedy, Jr. to serve as President Donald Trump’s HHS ...

Curie.Bio reveals $340M seed fund, Cullinan's zipalertinib succeeds in lung cancer trial, Benchling cuts 10% staff, I-Mab reduces workforce, Regulus shares Phase 1b data, Imvax raises $29M ...

Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson ...